SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies

Saved in:
Bibliographic Details
Published inJournal of hepatology Vol. 66; no. 1; p. S741
Main Authors Roberts, S.K, Cooper, C.L, Lawitz, E, Reddy, K.R, Thompson, A.J, Zeuzem, S, Jacobson, I.M, Ruane, P, Hyland, R.H, Stamm, L.M, Han, L, Brainard, D.M, Bräu, N, Asselah, T, Willems, B.E, Flamm, S, Bourlière, M, Foster, G.R, Gane, E.J, Manns, M, Gordon, S.C, Kowdley, K
Format Journal Article
LanguageEnglish
Published 2017
Subjects
Gastroenterology and Hepatology
Online AccessGet full text

Cover

More Information
ISSN:0168-8278
DOI:10.1016/S0168-8278(17)31974-8